[go: up one dir, main page]

WO2003040299A3 - Procede de selection de ligands d'hla-dp4 - Google Patents

Procede de selection de ligands d'hla-dp4 Download PDF

Info

Publication number
WO2003040299A3
WO2003040299A3 PCT/FR2002/003555 FR0203555W WO03040299A3 WO 2003040299 A3 WO2003040299 A3 WO 2003040299A3 FR 0203555 W FR0203555 W FR 0203555W WO 03040299 A3 WO03040299 A3 WO 03040299A3
Authority
WO
WIPO (PCT)
Prior art keywords
amino acid
hla
aromatic
applications
hydrophobic amino
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/FR2002/003555
Other languages
English (en)
Other versions
WO2003040299A2 (fr
Inventor
Bernard Maillere
Florence Castelli
Cecile Buhot
Bertrand Georges
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
SEDAC-Therapeutics
Commissariat a lEnergie Atomique et aux Energies Alternatives CEA
Original Assignee
Commissariat a lEnergie Atomique CEA
SEDAC-Therapeutics
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Commissariat a lEnergie Atomique CEA, SEDAC-Therapeutics filed Critical Commissariat a lEnergie Atomique CEA
Priority to CA002463705A priority Critical patent/CA2463705A1/fr
Priority to EP02795325A priority patent/EP1436626A2/fr
Priority to AU2002360128A priority patent/AU2002360128A1/en
Priority to US10/491,891 priority patent/US7718575B2/en
Publication of WO2003040299A2 publication Critical patent/WO2003040299A2/fr
Publication of WO2003040299A3 publication Critical patent/WO2003040299A3/fr
Anticipated expiration legal-status Critical
Priority to US12/719,712 priority patent/US20100324829A1/en
Ceased legal-status Critical Current

Links

Classifications

    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5008—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics
    • G01N33/5044—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing or evaluating the effect of chemical or biological compounds, e.g. drugs, cosmetics involving specific cell types
    • G01N33/5047—Cells of the immune system
    • G01N33/505—Cells of the immune system involving T-cells
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/5005—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells
    • G01N33/5091—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving human or animal cells for testing the pathological state of an organism
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Chemical & Material Sciences (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Cell Biology (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Microbiology (AREA)
  • Food Science & Technology (AREA)
  • Physics & Mathematics (AREA)
  • Analytical Chemistry (AREA)
  • Biotechnology (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Toxicology (AREA)
  • Tropical Medicine & Parasitology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Organic Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Zoology (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Physiology (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Peptides Or Proteins (AREA)
  • Investigating Or Analysing Biological Materials (AREA)

Abstract

Procédé de sélection de molécules ligand d'HLA-DP4 comprenant les étapes suivantes: (i) incubation d'HLA-DP4 purifiée avec un traceur de formule générale (I) Z1X1X2X3X4X5X6X7X8X9Z2, dans laquelle: Z1 et Z2, identiques ou différents, sont nuls ou représentent chacun un peptide de 1 à 100 acides aminés, X6 représente un acide aminé aromatique ou hydrophobe ou bien une cystéine, et X1 représente un acide aminé aromatique ou hydrophobe et/ou X9 représente un acide aminé aromatique ou hydrophobe, ou bien C, D, Q, S, T ou E, et X2,X3,X4,X5,X7 et X8 représentent chacun un acide aminé, en présence de différentes concentrations de molécule(s) à tester, (ii) séparation des différents complexes formés, (iii) révélation des complexes HLA-DP4/peptide traceur, et (iv) sélection des molécules ligand qui présentent une activité de liaison IC50 < 1000 nM, et ses applications.
PCT/FR2002/003555 2001-10-17 2002-10-17 Procede de selection de ligands d'hla-dp4 Ceased WO2003040299A2 (fr)

Priority Applications (5)

Application Number Priority Date Filing Date Title
CA002463705A CA2463705A1 (fr) 2001-10-17 2002-10-17 Procede de selection de ligands d'hla-dp4 et ses applications
EP02795325A EP1436626A2 (fr) 2001-10-17 2002-10-17 Procede de selection de ligands d'hla-dp4
AU2002360128A AU2002360128A1 (en) 2001-10-17 2002-10-17 Method of selecting hla-dp4 ligands and the applications thereof
US10/491,891 US7718575B2 (en) 2001-10-17 2002-10-17 Method of selecting HLA-DP4 ligands and the applications thereof
US12/719,712 US20100324829A1 (en) 2001-10-17 2010-03-08 Method of selecting hla-dp4 ligands and the applications thereof

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0113352A FR2830940B1 (fr) 2001-10-17 2001-10-17 Procede de selection de ligands d'hla-dp4 et ses applications
FR01/13352 2001-10-17

Related Child Applications (1)

Application Number Title Priority Date Filing Date
US12/719,712 Division US20100324829A1 (en) 2001-10-17 2010-03-08 Method of selecting hla-dp4 ligands and the applications thereof

Publications (2)

Publication Number Publication Date
WO2003040299A2 WO2003040299A2 (fr) 2003-05-15
WO2003040299A3 true WO2003040299A3 (fr) 2003-11-27

Family

ID=8868373

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/FR2002/003555 Ceased WO2003040299A2 (fr) 2001-10-17 2002-10-17 Procede de selection de ligands d'hla-dp4

Country Status (6)

Country Link
US (2) US7718575B2 (fr)
EP (1) EP1436626A2 (fr)
AU (1) AU2002360128A1 (fr)
CA (1) CA2463705A1 (fr)
FR (1) FR2830940B1 (fr)
WO (1) WO2003040299A2 (fr)

Families Citing this family (10)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
DE60044236D1 (de) 1999-02-17 2010-06-02 Csl Ltd Immunogene komplexe und methoden in bezug auf diese
US20040072262A1 (en) * 2002-10-11 2004-04-15 Montero-Julian Felix A. Methods and systems for detecting MHC class I binding peptides
WO2005033278A2 (fr) * 2003-09-30 2005-04-14 Ludwig Institute For Cancer Research Efficacite in vivo de ny-eso-1 associee a iscom
JP2007511760A (ja) * 2003-11-03 2007-05-10 ベックマン コールター インコーポレーティッド Ｍｈｃ結合ペプチドを検出するための溶液ベースの方法
WO2005111624A2 (fr) * 2004-05-07 2005-11-24 Beckman Coulter, Inc. Systeme de formation de pont de complexes d'histocompatibilite principale pour detecter une lyse mediee par les lymphocytes t de cellules presentant des antigenes
EP2226332A1 (fr) 2004-06-17 2010-09-08 Beckman Coulter, Inc. Épitopes de tuberculose par mycobacterium et ses procédés d'utilisation
FR2882628B1 (fr) * 2005-03-04 2011-03-18 Centre Nat Rech Scient Souris transgeniques et leurs applications comme modele experimental
DE102005041616B4 (de) * 2005-09-01 2011-03-17 Johannes-Gutenberg-Universität Mainz Melanom-assoziierte MHC Klasse I assoziierte Oligopeptide und für diese kodierende Polynukleotide und deren Verwendungen
FR2891462B1 (fr) * 2005-09-30 2009-10-16 Commissariat Energie Atomique Epitopes t cd4+ de la survivine et leurs applications
FR3008099B1 (fr) 2013-07-05 2020-08-07 Commissariat Energie Atomique Peptides immunogenes de l'antigene tumoral cycline b1

Family Cites Families (12)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6537764B1 (en) * 1995-01-19 2003-03-25 Children's Medical Center Corporation Method of identifying inhibitors of C—C chemokine receptor 3
US6027890A (en) * 1996-01-23 2000-02-22 Rapigene, Inc. Methods and compositions for enhancing sensitivity in the analysis of biological-based assays
WO1999018206A2 (fr) * 1997-10-08 1999-04-15 The Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Nouvel antigene du cancer humain ny eso-1/cag-3 et gene le codant
US6207391B1 (en) * 1998-03-31 2001-03-27 Tularik Inc. High-throughput screening assays for modulators of STAT4 and STAT6 activity
DK1123086T3 (da) * 1998-10-20 2010-06-14 Androclus Technologies S R L I Kunstige antigen-specifikke celler og tilhørende fremgangsmåder
JP4776852B2 (ja) * 2000-01-28 2011-09-21 アメリカ合衆国 癌抗原ｎｙｅｓｏ−１由来の新規ｍｈｃクラスｉｉ拘束ｔ細胞エピトープ
FR2843115B1 (fr) 2002-08-02 2007-11-09 Commissariat Energie Atomique Melange de peptides issus des proteines c et ns3 du virus de l'hepatite c et leurs applications
FR2874612A1 (fr) 2004-08-27 2006-03-03 Commissariat Energie Atomique Epitotes t cd4+ du vih restreints a hla-dp4 et leurs applications
WO2006075253A2 (fr) 2005-01-11 2006-07-20 Commissariat A L'energie Atomique Peptides destines a desensibiliser des sujets allergiques au poil de chien ou aux squames, et compositions contenant ces peptides
FR2881746B1 (fr) 2005-02-07 2007-04-13 Centre Nat Rech Scient Epitopes t cd4+des antigenes de latence de type i et ii du virus epstein-barr aptes a etre reconnus par la majorite des individus de la population caucasienne et leurs applications
FR2889959A1 (fr) 2005-09-01 2007-03-02 Commissariat Energie Atomique Epitopes t cd4+ des antigenes mage-a restreints a hla-dp4 et leurs applications
FR2891462B1 (fr) 2005-09-30 2009-10-16 Commissariat Energie Atomique Epitopes t cd4+ de la survivine et leurs applications

Non-Patent Citations (5)

* Cited by examiner, † Cited by third party
Title
CARBALLIDO JOSE M ET AL: "T cell epitope specificity of human allergic and nonallergic subjects to bee venom phospholipase A2.", JOURNAL OF IMMUNOLOGY, vol. 150, no. 8 PART 1, 1993, pages 3582 - 3591, XP002238429, ISSN: 0022-1767 *
CASTELLI FLORENCE A ET AL: "HLA-DP4, the most frequent HLA II molecule, defines a new supertype of peptide-binding specificity.", JOURNAL OF IMMUNOLOGY, vol. 169, no. 12, 15 December 2002 (2002-12-15), pages 6928 - 6934, XP002238415, ISSN: 0022-1767 *
FALK KIRSTEN ET AL: "Pool sequencing of natural HLA-DR, DQ, and DP ligands reveals detailed peptide motifs, constraints of processing, and general rules.", IMMUNOGENETICS, vol. 39, no. 4, 1994, pages 230 - 242, XP008007529, ISSN: 0093-7711 *
MARSHALL KEITH W ET AL: "Role of the polymorphic residues in HLA-DR molecules in allele-specific binding of peptide ligands.", JOURNAL OF IMMUNOLOGY, vol. 152, no. 10, 1994, pages 4946 - 4957, XP002212882, ISSN: 0022-1767 *
ZAROUR HASSANE M ET AL: "NY-ESO-1 encodes DRB1*0401-restricted epitopes recognized by melanoma-reactive CD4+ T cells.", CANCER RESEARCH, vol. 60, no. 17, 1 September 2000 (2000-09-01), pages 4946 - 4952, XP002236092, ISSN: 0008-5472 *

Also Published As

Publication number Publication date
AU2002360128A1 (en) 2003-05-19
CA2463705A1 (fr) 2003-05-15
US7718575B2 (en) 2010-05-18
EP1436626A2 (fr) 2004-07-14
FR2830940A1 (fr) 2003-04-18
WO2003040299A2 (fr) 2003-05-15
US20050059107A1 (en) 2005-03-17
US20100324829A1 (en) 2010-12-23
FR2830940B1 (fr) 2007-06-15

Similar Documents

Publication Publication Date Title
EP2368907A3 (fr) Anticorps anti-Abeta et leur utilisation
WO2003040299A3 (fr) Procede de selection de ligands d&#39;hla-dp4
CA2314129A1 (fr) Colorations luminescentes de proteines contenant des complexes de metaux de transition
EP2322569A3 (fr) Dérivés de polymère
WO2004101600A3 (fr) Nouveaux composes modifies par du poly(ethylene glycol) et leurs utilisations
CA2438910A1 (fr) Sterols amphoteres et leur utilisation dans la production de liposomes sensible au ph
WO1999015653A3 (fr) Homologues du ligand &#39;tie&#39;
WO2002074249A3 (fr) Produits pharmaceutiques et methodes pour le traitement de l&#39;hypoxie, et procedes de criblage prevus a cet effet
EP1939293A3 (fr) Protéine ZCYTO21 d&#39;interféron
EP2518155A3 (fr) Capteurs d&#39;enzyme, procédés de préparation et utilisation de tels capteurs, et procédés de détection de l&#39;activité protéase
WO2002011756A3 (fr) Compositions anti-plasmodium et procedes d&#39;utilisation
EP2314682A3 (fr) Protéines fluorescentes
Degli Esposti et al. A model for the molecular organization of cytochrome β-561 in chromaffin granule membranes
BR0309279A (pt) Macromoléculas em multicamadas e métodos para uso das mesmas
WO2003050283A3 (fr) Structure de presentation de sequences peptidiques souhaitees
ATE333469T1 (de) Verfahren zur reinigung hochanionischer proteine
Miyamoto et al. Basicity of N-Terminal amine in ATCUN peptide regulates stability constant of albumin-like Cu2+ complex
WO2005018552A3 (fr) Proteines liant l&#39;heparine : capteurs pour la detection de l&#39;heparine
WO2003002730A3 (fr) Methode de detection de l&#39;activite de la calpaine 3 dans un echantillon biologique et peptides pour la mise en oeuvre de ladite methode
WO2007052102A3 (fr) Proteines fluorescentes vertes modifiees et procedes d&#39;utilisation de celles-ci
WO2002061435A3 (fr) Vaccins purifies comportant des supermotifs structuraux a2
CA2379908A1 (fr) Preparation de complexes metalliques d&#39;acides amines obtenus par hydrolyse de proteines de soja
CA2384170A1 (fr) Sonde de visualisation de gmp cyclique et procede de detection et de quantification de gmp cyclique faisant intervenir cette sonde
AUPR775401A0 (en) Novel Epitopes and Uses Thereof
AU2001292118A1 (en) Dye-labelled peptide and its diagnostic use

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ OM PH PL PT RO RU SD SE SG SI SK SL TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR IE IT LU MC NL PT SE SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
DFPE Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101)
WWE Wipo information: entry into national phase

Ref document number: 2463705

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 2002795325

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2002795325

Country of ref document: EP

WWE Wipo information: entry into national phase

Ref document number: 10491891

Country of ref document: US

NENP Non-entry into the national phase

Ref country code: JP

WWW Wipo information: withdrawn in national office

Country of ref document: JP